How can we balance risk and benefit of interleukin-18 armored T cell therapies?
Experimental Biology and Medicine · 06.02.2026 · 251
DOI: 10.3389/ebm.2026.10938 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Experimental Biology and Medicine, online erschienen am 06.02.2026. Verfasst von Paulina Vicenova und 1 weiteren Autor:innen. Beteiligte Einrichtung: CAR Mechanics Lab, King's College London, School of Cancer and Pharmaceutical Sciences, London, United Kingdom. Hauptthemen laut MEDLINE: Interleukin-18, Immunotherapy, Adoptive, T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
CD19-specific CAR T cells engineered to secrete a constitutively active form of the pro-inflammatory cytokine, interleukin (IL)-18 have demonstrated impressive efficacy in a recent clinical trial involving subjects who had failed prior CAR T cell therapy. Corroborating these clinical data, preclinical studies of IL-18-armored CAR and T cell receptor-engineered T cells have demonstrated enhanced anti-tumor activity in several xenograft and syngeneic mouse cancer models. Interleukin-18 improves tumor clearance via direct effects on CAR T cells and indirect actions on cells on a variety of host immune cells, including natural killer, macrophage and dendritic cells. Compared to unarmored CAR T cells, IL-18-secreting CAR T cells are less exhausted, expand more efficiently and produce greater quantities of interferon (IFN)-γ. However, upregulated circulating IL-18 and its downstream mediator, IFN-γ, are also associated with systemic toxicities which have proven to be severe on occasions. In light of this, several groups have developed strategies that set out to restrict IL-18 release or biological activity to the tumor microenvironment. Among these, CAR T cells armored with NFAT-inducible IL-18 are now undergoing clinical testing. The evaluation of inducible or tumor-selective IL-18 deployment will show whether it is possible to minimize IL-18 related systemic toxicities while preserving localized amplification of anti-tumor activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CAR Mechanics Lab, King's College London, School of Cancer and Pharmaceutical Sciences, London, United Kingdom.
- Leucid Bio Ltd., Guy's Hospital, London, United Kingdom.
- Department of Immunology, Eastbourne Hospital, Eastbourne, East Sussex, United Kingdom.
Förderung
- Wellcome Trust
Zitieren
APA
Vicenova, P., & Maher, J. (2026). How can we balance risk and benefit of interleukin-18 armored T cell therapies?. Experimental Biology and Medicine, 251. https://doi.org/10.3389/ebm.2026.10938
Vancouver
Vicenova P, Maher J. How can we balance risk and benefit of interleukin-18 armored T cell therapies?. Experimental Biology and Medicine. 2026;251. doi:10.3389/ebm.2026.10938
BibTeX
@article{Vicenova2026,
author = {Vicenova, Paulina and Maher, John},
title = {How can we balance risk and benefit of interleukin-18 armored T cell therapies?},
journal = {Experimental Biology and Medicine},
year = {2026},
volume = {251},
doi = {10.3389/ebm.2026.10938}
}
EUVIMED